基础生物学在胃肠道癌症临床试验开发中的转化研究与应用。
Translational research and application of basic biology to clinical trial development in GI cancers.
作者信息
Smyth Elizabeth, Khan Khurum, Valeri Nicola
机构信息
Department of Gastrointestinal Cancer and Lymphoma, Royal Marsden, UK.
Gastrointestinal Cancer Biology and Genomics Team, Institute of Cancer Research, Royal Marsden, UK.
出版信息
Ann Transl Med. 2018 May;6(9):164. doi: 10.21037/atm.2018.05.05.
Abstract
Cancers of the gastrointestinal tract have limited available treatments and are often associated with a poor prognosis. Clinical trials and translational work associated with these trials provide the opportunity to increase understanding of the mechanisms of sensitivity and resistance to cytotoxic chemotherapy and targeted therapy in these diseases. In this review we discuss the rationale for intensive translational work within the context of academic clinical trials and the successes and challenges which have been associated with translational work at our institution over the past number of years. We reflect on tissue, plasma and radiological biomarker work including a novel patient derived organoid programme and discuss the iterative application of previous results to next generation trial design.
摘要
胃肠道癌症的可用治疗方法有限，且往往预后不良。与这些试验相关的临床试验和转化研究工作为增进对这些疾病中细胞毒性化疗和靶向治疗的敏感性及耐药性机制的理解提供了机会。在本综述中，我们讨论了在学术性临床试验背景下开展深入转化研究工作的基本原理，以及过去几年我们机构在转化研究工作中所取得的成功与面临的挑战。我们思考了组织、血浆和放射学生物标志物研究工作，包括一项新的患者来源类器官计划，并讨论了将先前结果迭代应用于下一代试验设计的情况。
相似文献
1
Translational research and application of basic biology to clinical trial development in GI cancers.基础生物学在胃肠道癌症临床试验开发中的转化研究与应用。
Ann Transl Med. 2018 May;6(9):164. doi: 10.21037/atm.2018.05.05.
2
Clinical applications of circulating tumor-derived DNA in the management of gastrointestinal cancers - current evidence and future directions.循环肿瘤来源DNA在胃肠道癌症管理中的临床应用——当前证据与未来方向
Front Oncol. 2022 Sep 29;12:970242. doi: 10.3389/fonc.2022.970242. eCollection 2022.
3
Integrating cfDNA liquid biopsy and organoid-based drug screening reveals PI3K signaling as a promising therapeutic target in colorectal cancer.整合 cfDNA 液体活检和类器官药物筛选揭示了 PI3K 信号通路作为结直肠癌有前途的治疗靶点。
J Transl Med. 2024 Feb 3;22(1):132. doi: 10.1186/s12967-023-04675-6.
4
High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.ctDNA 中高 EGFR 突变 MAF 和高 T790M 敏感突变比例预示着更好的第三代 TKI 治疗结局。
Thorac Cancer. 2020 Jun;11(6):1503-1511. doi: 10.1111/1759-7714.13418. Epub 2020 Apr 14.
5
High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.在晚期非小细胞肺癌中，基于循环肿瘤 DNA 的下一代测序检测与组织下一代测序检测鉴定出的可操作基因组改变具有高度一致性：韩国肺液与有创性活检项目。
Cancer. 2021 Aug 15;127(16):3019-3028. doi: 10.1002/cncr.33571. Epub 2021 Apr 7.
6
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.液体活检能否通过低深度全基因组测序检测肉瘤患者的循环肿瘤DNA？一项初步评估。
Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21.
7
Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer.晚期胆管癌中循环肿瘤DNA与组织基因组分析的一致性
J Hepatol. 2025 Apr;82(4):649-657. doi: 10.1016/j.jhep.2024.10.020. Epub 2024 Oct 21.
8
Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.使用血浆 ctDNA、参考标准品和源自正常血浆的合成系列稀释样本，对一种商用的下一代测序液体活检平台进行分析性能评估。
BMC Cancer. 2020 Oct 1;20(1):945. doi: 10.1186/s12885-020-07445-5.
9
Promising preclinical patient-derived organoid (PDO) and xenograft (PDX) models in upper gastrointestinal cancers: progress and challenges.在上消化道癌症中具有前景的临床前患者来源的类器官 (PDO) 和异种移植 (PDX) 模型：进展与挑战。
BMC Cancer. 2023 Dec 7;23(1):1205. doi: 10.1186/s12885-023-11434-9.
10
REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer.REMARRY 和 PURSUIT 试验：针对血浆 RAS 野生型转移性结直肠癌患者，采用帕尼单抗联合伊立替康进行液体活检指导的抗表皮生长因子受体（EGFR）治疗的再挑战。
BMC Cancer. 2021 Jun 7;21(1):674. doi: 10.1186/s12885-021-08395-2.
引用本文的文献
1
evidence: Repression of mucosal immune responses in mice with colon cancer following sustained administration of .证据：持续给予……后，结肠癌小鼠的黏膜免疫反应受到抑制。
Saudi J Biol Sci. 2021 Aug;28(8):4751-4761. doi: 10.1016/j.sjbs.2021.04.090. Epub 2021 May 6.
2
Preclinical models as patients' avatars for precision medicine in colorectal cancer: past and future challenges.临床前模型作为精准医学在结直肠癌中患者替身：过去和未来的挑战。
J Exp Clin Cancer Res. 2021 Jun 5;40(1):185. doi: 10.1186/s13046-021-01981-z.
3
Concise update on colorectal cancer epidemiology.结直肠癌流行病学的简要更新。
Ann Transl Med. 2019 Nov;7(21):609. doi: 10.21037/atm.2019.07.91.
4
Back to the Colorectal Cancer Consensus Molecular Subtype Future.回到结直肠癌共识分子亚型的未来。
Curr Gastroenterol Rep. 2019 Jan 30;21(2):5. doi: 10.1007/s11894-019-0674-9.
本文引用的文献
1
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.患者来源的类器官模型可模拟转移性胃肠道癌症的治疗反应。
Science. 2018 Feb 23;359(6378):920-926. doi: 10.1126/science.aao2774.
2
Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice.探讨在常规临床实践中进行胃肠恶性肿瘤肿瘤分子谱分析的可行性。
Ann Oncol. 2018 Jan 1;29(1):230-236. doi: 10.1093/annonc/mdx631.
3
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.抗程序性死亡蛋白-1（PD-1）抗体帕博利珠单抗在晚期结直肠癌患者中的安全性及抗肿瘤活性
PLoS One. 2017 Dec 28;12(12):e0189848. doi: 10.1371/journal.pone.0189848. eCollection 2017.
4
Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer.胃癌中微卫星不稳定性与临床病理特征及总生存关系的荟萃分析。
Br J Surg. 2018 Feb;105(3):159-167. doi: 10.1002/bjs.10663. Epub 2017 Nov 1.
5
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.纳武利尤单抗治疗既往至少两种化疗方案治疗失败或不耐受的晚期胃或胃食管结合部腺癌患者（ONO-4538-12，ATTRACTION-2）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6.
6
Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study.前瞻性 II 期研究中regorafenib 治疗耐药转移性结直肠癌患者的功能成像和循环生物标志物反应。
Gut. 2018 Aug;67(8):1484-1492. doi: 10.1136/gutjnl-2017-314178. Epub 2017 Aug 8.
7
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.错配修复缺陷可预测实体瘤对程序性死亡受体1（PD-1）阻断疗法的反应。
Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.
8
Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.错配修复缺陷、微卫星不稳定与生存：英国医学研究理事会辅助胃输注化疗（MAGIC）试验的探索性分析
JAMA Oncol. 2017 Sep 1;3(9):1197-1203. doi: 10.1001/jamaoncol.2016.6762.
9
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.可切除食管胃腺癌围手术期化疗联合或不联合贝伐单抗（英国医学研究委员会ST03）：一项多中心、开放标签、随机2-3期试验的主要分析结果
Lancet Oncol. 2017 Mar;18(3):357-370. doi: 10.1016/S1470-2045(17)30043-8. Epub 2017 Feb 3.
10
Human tissues in a dish: The research and ethical implications of organoid technology.器官芯片技术的研究与伦理问题：培养皿中的人类组织
Science. 2017 Jan 20;355(6322). doi: 10.1126/science.aaf9414.
Zotero 插件